Grifols (GIFLF) Enterprise Value (2010 - 2025)
Grifols (GIFLF) reported Enterprise Value of -$965.0 million for Q4 2025, up 8.41% on a YoY basis from -$890.1 million in Q4 2024, and up 8.41% quarter-over-quarter from -$1.1 billion in Q4 2024.
Grifols (GIFLF) Enterprise Value (2010 - 2025) Analysis & Trends
Grifols has reported Enterprise Value for 16 years, with the latest figure at -$965.0 million in Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 8.41% year-over-year to -$965.0 million; the trailing twelve-month figure through Dec 2025 stood at -$965.0 million (up 8.41% YoY), and the FY2025 full-year result was -$965.0 million, up 8.41% from the prior year.
- Enterprise Value for Q4 2025 stood at -$965.0 million, up from -$1.1 billion in the prior quarter.
- The five-year high for Enterprise Value was -$594.6 million in Q4 2023, with the low at -$3.0 billion in Q4 2021.
- Historically, Enterprise Value has averaged -$1.3 billion across 5 years, with a median of -$965.0 million in 2025.
- Annual changes were most pronounced in 2021 — Enterprise Value slumped 346.88% — and 2022, when it soared 80.09%.
- Grifols' Enterprise Value stood at -$3.0 billion in 2021, then soared by 80.09% to -$604.7 million in 2022, then climbed by 1.66% to -$594.6 million in 2023, then plunged by 77.2% to -$1.1 billion in 2024, then increased by 8.41% to -$965.0 million in 2025.
- The last three Enterprise Value figures came in at -$965.0 million (Q4 2025), -$1.1 billion (Q4 2024), and -$594.6 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Grifols | - | - | - | -964.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -964.99 Mn |
| Dec 31, 2024 | -1.05 Bn |
| Dec 31, 2023 | -594.61 Mn |
| Dec 31, 2022 | -604.66 Mn |
| Dec 31, 2021 | -3.04 Bn |
| Dec 31, 2020 | 1.23 Bn |
| Sep 30, 2020 | 835.58 Mn |
| Mar 31, 2020 | 1.95 Bn |
| Dec 31, 2019 | 1.12 Bn |
| Sep 30, 2019 | -305.89 Mn |
| Mar 31, 2019 | 339.22 Mn |
| Dec 31, 2018 | -665.06 Mn |
| Sep 30, 2018 | -734.00 Mn |
| Jun 30, 2018 | -776.98 Mn |
| Mar 31, 2018 | 550.34 Mn |
| Dec 31, 2017 | -1.05 Bn |
| Jun 30, 2017 | -819.13 Mn |
| Mar 31, 2017 | -156.72 Mn |
| Dec 31, 2016 | -962.14 Mn |
| Sep 30, 2016 | -1.00 Bn |